SEC EDGARJUN 12 min read$JAZZ

Patil Neena M sold $282K of JAZZ

Patil Neena M (EVP & Chief Legal Officer) sold 1,192 shares of Jazz Pharmaceuticals plc (JAZZ) at $236.97 ($0.28M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Patil Neena M

Published Jun 1, 2026, 8:09 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 1, 2026, 8:26 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$JAZZ

Neutral

high confidence

Mentioned

$JAZZ

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$JAZZNeutralLow

Why it matters

The event is primarily informational for monitoring insider activity; it does not introduce new guidance, trial results, regulatory actions, or deal terms.

Market read

Traders may note the sale for sentiment/positioning, but the 10b5-1 structure reduces the likelihood of a fundamental read-through.

What to watch

The disclosure does not indicate whether the executive sold for diversification, tax planning, or routine liquidity; without additional context, signal quality is low.

Relevance 6/10Novelty 2/10Timing: Filed June 1; sale executed May 28

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by an EVP under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JAZZNeutralHigh confidence

Context

Jazz Pharmaceuticals disclosed an EVP & Chief Legal Officer open-market sale of 1,192 shares under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a routine Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific developments beyond the sale details.

Market effects

Sector

Minimal; insider Form 4 activity does not reset sector expectations for biotech/pharma.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can coincide with broader internal caution, so traders may watch for clustering of similar filings.

Key entities

issuer
Jazz Pharmaceuticals plc
Subject of the Form 4 insider transaction disclosure.
insider
Patil Neena M
EVP & Chief Legal Officer who sold 1,192 shares on May 28, 2026.

Read at source ← All news

SEP 23

$JAZZLowAI 8/10

Jazz Pharmaceuticals extends $1.9B in loans to 2033

Jazz Pharmaceuticals extended and repriced its $1.9B loan, pushing the maturity date to 2033 and reducing the interest rate by 50 basis points. The company borrowed an additional $273.3M to refinance existing debt, with the new tranche amortizing over 25 years.

stocktitan.net1 min

SEP 23

$JAZZMed

New Data Highlights the Dosing Flexibility of Low-Sodium Oxybate

Jazz Pharmaceuticals presented data at SLEEP 2026 showing Xywav's dosing flexibility for narcolepsy and idiopathic hypersomnia, with stable regimens achievable in ~42 days. Real-world data indicates 91% use twice-nightly regimens, but clinicians often customize doses. Studies also show cardiovascular benefits of low-sodium oxybate. According to Jazz, Xywav's individualized dosing can improve patient outcomes.

sleepreviewmag.com2 min

SEP 20

$JAZZHighAI 8/10

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals (JAZZ) targets $5B opportunity for zanidatamab, with oncology revenue exceeding $1B. The company expects strong adoption of the triplet regimen and sees limited near-term competition. Jazz also reported 40% growth for Zepzelca and strong early adoption for Modeyso. The company generated $824M cash in H1 and raised $1B through a convertible offering, with plans for further investments and acquisitions.

finance.yahoo.com3 min

SEP 20

$JAZZHighAI 8/10

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals (JAZZ) raised its revenue estimate for Ziihera to $3B-$5B, citing potential expansion in multiple cancer types. The company expects Ziihera to become a first-line standard of care for HER2-positive gastroesophageal adenocarcinoma. Jazz also announced pipeline expansions in epilepsy and sleep-wake disorders, including new clinical trials and formulations.

finance.yahoo.com2 min

SEP 18

$JAZZHighAI 9/10

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

Jazz Pharmaceuticals (JAZZ) acquired Actio Biosciences for $820M, with potential $500M in milestone payments, to gain control of ABS-1230, a treatment for rare childhood epilepsy. Jazz reported Q2 revenue of $1.2B, up 16% YoY, and raised 2026 guidance to $4.6B-$4.75B. The company also acquired Chimerix for $944M in 2025. ABS-1230 is in Phase 1b/2a trials, with early results showing seizure reductions. Jazz trades at ~9.5x forward earnings, offering growth potential but with clinical risks.

fool.com3 min